May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
A Poly (Ortho Esters)–Based Drug Delivery System as an Adjunct Treatment in Filtering Surgery: Comparison Between 5–Fluorouracil and 5–Chlorouracil
Author Affiliations & Notes
  • M. Berdugo–Polak
    Inserm u 598, Institut des Cordeliers, Paris, France
  • F. Valamanesh
    Fondation Ophtalmologique A. de Rothschild, Paris, France
  • O. Felt
    Department of Pharmaceutical Technology and Biopharmaceutics, School of Pharmacy, University of Geneva, Geneva, Switzerland
  • P. Rat
    Faculté de Pharmacie, Paris, France
  • C. Jolly
    Laboratoire d'Imagerie Paramétrique, UMR 7623, Paris, France
  • A. Saied
    Laboratoire d'Imagerie Paramétrique, UMR 7623, Paris, France
  • G. Renard
    Hôtel–Dieu Hospital, Paris, France
  • R. Gurny
    Department of Pharmaceutical Technology and Biopharmaceutics, School of Pharmacy, University of Geneva, Geneva, Switzerland
  • F. Behar–Cohen
    Inserm u 598, Institut des Cordeliers, Paris, France
    Fondation Ophtalmologique A. de Rothschild, Paris, France
  • Footnotes
    Commercial Relationships  M. Berdugo–Polak, None; F. Valamanesh, None; O. Felt, None; P. Rat, None; C. Jolly, None; A. Saied, None; G. Renard, None; R. Gurny, None; F. Behar–Cohen, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 61. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Berdugo–Polak, F. Valamanesh, O. Felt, P. Rat, C. Jolly, A. Saied, G. Renard, R. Gurny, F. Behar–Cohen; A Poly (Ortho Esters)–Based Drug Delivery System as an Adjunct Treatment in Filtering Surgery: Comparison Between 5–Fluorouracil and 5–Chlorouracil . Invest. Ophthalmol. Vis. Sci. 2005;46(13):61.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To study the in vitro anti proliferation effects and the in vivo influence in an experimental model of filtering surgery in the rabbit eye of 5–fluorouracil (5–FU) and 5–chlorouracil (5–CU). Methods: In vitro cell toxicity and anti proliferation effects of various 5–CU and 5–FU concentrations is evaluated by MTT test, Neutral Red test, Hoechst test and direct cell counting after 24 and 72h incubation. For the in vivo studies, trabeculectomy is performed in pigmented rabbit eyes. 200µl of polyorthoesters (POE) containing 1% wt/wt 5–FU or 5–CU are injected under the conjunctival flap on completion of the filtering surgery. Ocular inflammatory reaction, intraocular pressure (IOP) and bleb persistence are monitored after surgery for a period of 34 days. A comparison between rabbit eyes treated with POE/5CU or trabeculectomy alone is performed during a 10 months period using high frequency echography. Results: In vitro tests showed that 5FU has a higher anti proliferation effect and cell toxicity than 5CU. While 5CU increases the apoptotic rate of the cultured Tenon’s capsule cells, 5FU induces evident cell necrosis. In vivo, treatment with POE/5CU or POE/5FU retained a lower IOP when compared to trabeculectomy alone or trabeculectomy with injection of empty POE. One month post surgery, IOP in the POE/5CU group was 6.20 +/– 2.68 mmHg, it was 3.42 +/– 1.07 mmHg in the POE/5FU group, 9.19 +/– 4.12 mmHg in the empty POE group. The "only trabeculectomy" group had an IOP of 8.38 +/– 4.12 mmHg. 6 months later, IOP was maintained significantly lower in the POE/5CU group related to the control. Conclusions: 5–FU and 5–CU in POE stabilize the decrease of IOP after glaucoma filtering surgery in the rabbit eye. 5–FU has a more marked inhibitory effect on cell proliferation of fibroblasts from Tenon’s capsule than 5–CU. In vivo however, 5–CU also induces a sustained IOP decrease.

Keywords: intraocular pressure • drug toxicity/drug effects • clinical laboratory testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×